How Cabozantinib is Being Used in Practice for Patients With RCC

Daniel James George, MD, professor of Medicine, professor in Surgery, Duke University School of Medicine, discusses how cabozantinib (Cabometyx) is currently being used in practice for patients with renal cell carcinoma (RCC).

Related Videos
Chandler H. Park, MD, an expert on renal cell carcinoma
Related Content